[On the inhibitory effect of phosphate compounds on experimental vascular calcinosis].
D000818:Animals; D001011:Aorta / Q000378:metabolism / Q000473:pathology; D001158:Arteries / Q000473:pathology*; D002114:Calcinosis / Q000139:chemically induced / Q000473:pathology*; D003331:Coronary Vessels / Q000473:pathology; D004097:Dihydrotachysterol / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D011756:Diphosphates / Q000494:pharmacology*; D005260:Female; D005994:Glycerophosphates / Q000494:pharmacology; D006652:Histological Techniques; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D007668:Kidney / Q000473:pathology*; D009206:Myocardium / Q000473:pathology; D009397:Nephrocalcinosis / Q000139:chemically induced / Q000473:pathology*; D010710:Phosphates / Q000494:pharmacology; D010744:Phosphoric Monoester Hydrolases / Q000378:metabolism; D011651:Pulmonary Artery / Q000473:pathology; D051381:Rats; D014652:Vascular Diseases / Q000139:chemically induced / Q000473:pathology*
D011756:Diphosphates; D005994:Glycerophosphates; D010710:Phosphates; D010744:Phosphoric Monoester Hydrolases; D004097:Dihydrotachysterol
Zur Hemmwirkung von Phosphatverbindungen auf die experimentelle Gefässcalcinose.